- Home
- PNI vs SERA Comparison
PNI vs SERA Comparison
Compare PNI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- SERA
- Stock Information
- Founded
- PNI 2002
- SERA 2008
- Country
- PNI United States
- SERA United States
- Employees
- PNI N/A
- SERA N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- SERA Precision Instruments
- Sector
- PNI Finance
- SERA Health Care
- Exchange
- PNI Nasdaq
- SERA Nasdaq
- Market Cap
- PNI 75.3M
- SERA 87.4M
- IPO Year
- PNI N/A
- SERA 2021
- Fundamental
- Price
- PNI $6.66
- SERA $1.91
- Analyst Decision
- PNI
- SERA
- Analyst Count
- PNI 0
- SERA 0
- Target Price
- PNI N/A
- SERA N/A
- AVG Volume (30 Days)
- PNI 26.4K
- SERA 259.6K
- Earning Date
- PNI 01-01-0001
- SERA 05-07-2025
- Dividend Yield
- PNI 4.76%
- SERA N/A
- EPS Growth
- PNI N/A
- SERA N/A
- EPS
- PNI N/A
- SERA N/A
- Revenue
- PNI N/A
- SERA $115,000.00
- Revenue This Year
- PNI N/A
- SERA $390.13
- Revenue Next Year
- PNI N/A
- SERA $440.54
- P/E Ratio
- PNI N/A
- SERA N/A
- Revenue Growth
- PNI N/A
- SERA N/A
- 52 Week Low
- PNI $6.03
- SERA $1.53
- 52 Week High
- PNI $7.89
- SERA $9.53
- Technical
- Relative Strength Index (RSI)
- PNI 43.59
- SERA 37.88
- Support Level
- PNI $6.65
- SERA $1.53
- Resistance Level
- PNI $6.75
- SERA $2.47
- Average True Range (ATR)
- PNI 0.06
- SERA 0.18
- MACD
- PNI -0.00
- SERA 0.01
- Stochastic Oscillator
- PNI 23.81
- SERA 40.64
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.